Featured Articles

Pfizer Japan Inc. and Eisai Co., Ltd. have announced a new collaboration to co-promote the migraine treatment Nurtec OD Tablet 75mg (rimegepant sulfate hydrate) across Japan beginning…
Read More...

Lundbeck has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Lu AH69593, its investigational oral orexin 2 receptor agonist being developed to treat…
Read More...

GSK has received U.S. Food and Drug Administration (FDA) approval for Jideytro (zidesamtinib), a next-generation targeted therapy for adults with locally advanced or metastatic…
Read More...

Bristol Myers Squibb (BMS) is significantly expanding its artificial intelligence capabilities with the deployment of a second NVIDIA DGX SuperPOD, strengthening its efforts to…
Read More...

Novo Nordisk has filed a lawsuit against Eli Lilly and Company and Lilly USA in the United States, alleging that the pharmaceutical giant's advertising for its blockbuster diabetes and…
Read More...

Merck, known as MSD outside the United States and Canada, has announced that the U.S. Food and Drug Administration (FDA) has approved LIPFENDRA (enlicitide) 20 mg tablets for adults…
Read More...

Novartis has announced that the US Food and Drug Administration (FDA) has granted traditional approval to Fabhalta (iptacopan) for adults with primary immunoglobulin A nephropathy…
Read More...

Novo Nordisk has announced that the European Commission (EC) has approved Wegovy® pill (oral semaglutide 25 mg) for the treatment of adults living with obesity or overweight with at…
Read More...

Teva Pharmaceuticals International GmbH has entered into a global licensing agreement with Polpharma Biologics International AG for exclusive commercialization rights to Polpharma…
Read More...

Bayer has formed a strategic clinical trials alliance with the University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, marking the company’s first collaboration of…
Read More...

Ipsen has agreed to acquire Memo Therapeutics AG in a deal designed to strengthen its rare disease pipeline with potravitug, a Phase II clinical-stage monoclonal antibody for BK…
Read More...

Novartis has received European Commission approval for Itvisma® (onasemnogene abeparvovec), expanding access to gene replacement therapy for children, teenagers and adults living with…
Read More...

Sanofi has reported positive Phase 3 results for Nexviazyme, also known as avalglucosidase alfa, in infants with infantile-onset Pompe disease, a rare and life-threatening genetic…
Read More...

Merck KGaA, Darmstadt, Germany, has announced a definitive agreement to acquire U.S.-based life sciences company Bio-Techne Corporation in an all-cash transaction valued at…
Read More...

Ionis Partners with Recordati to Commercialize Alexander Disease Therapy Outside U.S. Ionis Pharmaceuticals has entered into a strategic licensing agreement with Recordati to expand…
Read More...

uniQure has reported encouraging early clinical results from its experimental gene therapy AMT-260, offering new hope for patients living with refractory mesial temporal lobe epilepsy…
Read More...

Jazz Pharmaceuticals and AbCellera have entered into a new research collaboration aimed at developing next-generation antibody-based treatments for gastrointestinal (GI) cancers and…
Read More...

Biogen has agreed to acquire private biotechnology company RayThera in a deal valued at up to $1 billion, strengthening the company's growing focus on immunology and expanding its…
Read More...

Eli Lilly and Company has acquired 4E Therapeutics, a privately held neuroscience biotechnology company focused on developing next-generation therapies for chronic pain, strengthening…
Read More...

Johnson & Johnson has announced plans to invest more than $1 billion in Jacksonville, Florida, to expand its Vision business operations and strengthen domestic manufacturing,…
Read More...